ORGOOrganogenesis Holdings Inc.vs its industry peers
A metric-by-metric comparison of Organogenesis Holdings Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORGO본 종목 | $175M#6 | — | 1.2x#6 | 0.3x#1 | 17.0%#2 | 4011.1%#1 | 7.9%#1 | 25.0%#1 | 23.2%#1 | — | -70.5%#5 | — |
| BRVE | $2.5B#1 | — | — | — | — | — | — | — | — | — | — | — |
| PEPG | $204M#2 | — | 1.7x#7 | — | — | 0.4%#5 | — | -75.0%#7 | — | — | 57.2%#2 | — |
| NKTX | $198M#3 | — | 0.8x#3 | — | — | 4.3%#4 | — | -42.0%#5 | — | — | 44.3%#3 | — |
| ORMP | $195M#4 | 1.1x#1 | 1.0x#5 | 97.5x#3 | — | 573.1%#2 | -754.4%#2 | 0.0%#2 | -4.4%#2 | — | 106.2%#1 | — |
| TNXP | $195M#5 | — | 0.9x#4 | 14.9x#2 | 29.8%#1 | 4.6%#3 | -959.1%#3 | -55.8%#6 | -234.8%#3 | — | -58.9%#4 | — |
| CNTN | $171M#7 | — | 0.4x#1 | — | — | -194.5%#6 | — | -7.9%#4 | — | — | — | — |
| RNA | $163M#8 | — | 0.8x#2 | — | — | — | — | 0.0%#3 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice